<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bibli, S. I.</style></author><author><style face="normal" font="default" size="100%">Andreadou, I.</style></author><author><style face="normal" font="default" size="100%">Chatzianastasiou, A.</style></author><author><style face="normal" font="default" size="100%">Tzimas, C.</style></author><author><style face="normal" font="default" size="100%">Sanoudou, D.</style></author><author><style face="normal" font="default" size="100%">Kranias, E.</style></author><author><style face="normal" font="default" size="100%">Brouckaert, P.</style></author><author><style face="normal" font="default" size="100%">Coletta, C</style></author><author><style face="normal" font="default" size="100%">Szabo, C.</style></author><author><style face="normal" font="default" size="100%">Kremastinos, D.T.</style></author><author><style face="normal" font="default" size="100%">Iliodromitis, E.K.</style></author><author><style face="normal" font="default" size="100%">Papapetropoulos, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Cardioprotection by H2S engages a cGMP-dependent protein kinase G/phospholamban pathway</style></title><secondary-title><style face="normal" font="default" size="100%">Cardiovasc ResCardiovasc ResCardiovasc Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Cardiovascular research</style></alt-title><short-title><style face="normal" font="default" size="100%">Cardiovascular researchCardiovascular research</style></short-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Calcium-Binding Proteins/deficiency/genetics/*metabolism</style></keyword><keyword><style  face="normal" font="default" size="100%">Cyclic GMP-Dependent Protein Kinases/antagonists &amp; inhibitors/*metabolism</style></keyword><keyword><style  face="normal" font="default" size="100%">Cyclic GMP/metabolism</style></keyword><keyword><style  face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style  face="normal" font="default" size="100%">Enzyme Activation</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Hydrogen Sulfide/metabolism/*pharmacology</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style  face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style  face="normal" font="default" size="100%">Myocardial Infarction/enzymology/pathology/*prevention &amp; control</style></keyword><keyword><style  face="normal" font="default" size="100%">Myocardial Reperfusion Injury/enzymology/pathology/*prevention &amp; control</style></keyword><keyword><style  face="normal" font="default" size="100%">Myocytes, Cardiac/*drug effects/enzymology/pathology</style></keyword><keyword><style  face="normal" font="default" size="100%">Nitric Oxide Synthase Type III/antagonists &amp; inhibitors/genetics/metabolism</style></keyword><keyword><style  face="normal" font="default" size="100%">Nitric Oxide/metabolism</style></keyword><keyword><style  face="normal" font="default" size="100%">Phosphorylation</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Kinase Inhibitors/pharmacology</style></keyword><keyword><style  face="normal" font="default" size="100%">Rabbits</style></keyword><keyword><style  face="normal" font="default" size="100%">Signal Transduction/*drug effects</style></keyword><keyword><style  face="normal" font="default" size="100%">Species Specificity</style></keyword><keyword><style  face="normal" font="default" size="100%">Sulfides/metabolism/*pharmacology</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jun 1</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">106</style></volume><pages><style face="normal" font="default" size="100%">432-42</style></pages><isbn><style face="normal" font="default" size="100%">1755-3245 (Electronic)0008-6363 (Linking)</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">AIMS: H2S is known to confer cardioprotection; however, the pathways mediating its effects in vivo remain incompletely understood. The purpose of the present study is to evaluate the contribution of cGMP-regulated pathways in the infarct-limiting effect of H2S in vivo. METHODS AND RESULTS: Anaesthetized rabbits were subjected to myocardial ischaemia (I)/reperfusion (R), and infarct size was determined in control or H2S-exposed groups. The H2S donor sodium hydrosulfide (NaHS, an agent that generates H2S) increased cardiac cGMP and reduced the infarct size. The cGMP-dependent protein kinase (PKG)-I inhibitor DT2 abrogated the protective effect of NaHS, whereas the control peptide TAT or l-nitroarginine methyl ester (l-NAME) did not alter the effect of NaHS. Moreover, the KATP channel inhibitor, glibenclamide, partially reversed the effects of NaHS, whereas inhibition of mitochondrial KATP did not modify the NaHS response. NaHS enhanced phosphorylation of phospholamban (PLN), in a PKG-dependent manner. To further investigate the role of PLN in H2S-mediated cardioprotection, wild-type and PLN KO mice underwent I/R. NaHS did not exert cardioprotection in PLN KO mice. Unlike what was observed in rabbits, genetic or pharmacological inhibition of eNOS abolished the infarct-limiting effect of NaHS in mice. CONCLUSIONS: Our findings demonstrate (i) that administration of NaHS induces cardioprotection via a cGMP/PKG/PLN pathway and (ii) contribution of nitric oxide to the H2S response is species-specific.</style></abstract><accession-num><style face="normal" font="default" size="100%">25870184</style></accession-num><notes><style face="normal" font="default" size="100%">Bibli, Sofia-IrisAndreadou, IoannaChatzianastasiou, AthanasiaTzimas, ChristosSanoudou, DespinaKranias, EvangeliaBrouckaert, PeterColetta, CiroSzabo, CsabaKremastinos, Dimitrios ThIliodromitis, Efstathios KPapapetropoulos, AndreasengR01 GM107846/GM/NIGMS NIH HHS/R01 HL026057/HL/NHLBI NIH HHS/R01 HL064018/HL/NHLBI NIH HHS/Research Support, N.I.H., ExtramuralResearch Support, Non-U.S. Gov'tEngland2015/04/15 06:00Cardiovasc Res. 2015 Jun 1;106(3):432-42. doi: 10.1093/cvr/cvv129. Epub 2015 Apr 13.</style></notes><custom2><style face="normal" font="default" size="100%">4447809</style></custom2><auth-address><style face="normal" font="default" size="100%">Faculty of Pharmacy, University of Athens, Panepistimiopolis, Zografou, Athens 15771, Greece.Faculty of Pharmacy, University of Athens, Panepistimiopolis, Zografou, Athens 15771, Greece jandread@pharm.uoa.gr apapapet@pharm.uoa.gr.Faculty of Medicine, First Department of Critical Care and Pulmonary Services, Evangelismos Hospital, University of Athens, Athens, Greece.Molecular Biology Department, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.Molecular Biology Department, Biomedical Research Foundation of the Academy of Athens, Athens, Greece Department of Pharmacology, Faculty of Medicine, University of Athens, Athens, Greece.Molecular Biology Department, Biomedical Research Foundation of the Academy of Athens, Athens, Greece Department of Pharmacology and Cell Biophysics, College of Medicine, University of Cincinnati, Cincinnati, OH, USA.Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium Department of Molecular Biomedical Research, VIB, Ghent, Belgium.Department of Anesthesiology University of Texas Medical Branch, Galveston, TX, USA Shriners Burns Hospital for Children, Galveston, TX, USA.Faculty of Medicine, Second Department of Cardiology, Attikon University Hospital, University of Athens, Athens, Greece.Faculty of Pharmacy, University of Athens, Panepistimiopolis, Zografou, Athens 15771, Greece Molecular Biology Department, Biomedical Research Foundation of the Academy of Athens, Athens, Greece jandread@pharm.uoa.gr apapapet@pharm.uoa.gr.</style></auth-address></record></records></xml>